The Tumor Immunity Therapy Market is experiencing strong expansion as cancer immunotherapy becomes an increasingly important component of modern oncology. Tumor immunity therapies work by stimulating, restoring, or directing the immune system to recognize and attack malignant cells. The growing global cancer burden, increasing awareness of immunotherapy, and continued investment in oncology research are creating significant opportunities for market participants.

According to WiseGuyReports, the global Tumor Immunity Therapy Market was valued at USD 21.22 billion in 2024 and is projected to reach USD 150.41 billion by 2032. The market is forecast to expand at a CAGR of 27.74%, reflecting the rapid adoption of innovative immunotherapeutic approaches.

Technological innovation represents a major factor supporting market development. Immune checkpoint inhibitors, T-cell adoptive immunotherapy, oncolytic viruses, and immune modulators are expanding the therapeutic options available to cancer patients. Checkpoint inhibitors currently represent a particularly important segment. WiseGuyReports indicates that this segment generated USD 10.58 billion in revenue in 2024 and is projected to reach USD 46.91 billion by 2032.

The market is also benefiting from the growing emphasis on personalized medicine. Patient stratification and biomarker-based treatment selection can help healthcare professionals identify patients who may respond to particular immunotherapies. Combination treatment strategies are also gaining attention because they can potentially improve therapeutic outcomes by targeting cancer through multiple biological pathways.

By indication, the market includes melanoma, non-small cell lung cancer, colorectal cancer, bladder cancer, and renal cell carcinoma. Melanoma has represented a leading indication, supported by the availability of effective immunotherapy options and continued clinical research. Tumor immunity therapies are also increasingly being investigated across additional cancer types, broadening the potential addressable patient population.

North America remains an important regional market because of its established healthcare infrastructure, pharmaceutical and biotechnology presence, and substantial oncology research activity. Meanwhile, Asia-Pacific is expected to demonstrate rapid growth as cancer incidence rises, awareness improves, healthcare investment increases, and clinical research expands.

Overall, continued innovation, increasing cancer prevalence, government research support, and growing adoption of personalized and targeted therapies are expected to sustain the strong growth trajectory of the Tumor Immunity Therapy Market.